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INTRODUC TION
Progressive multifocal leukoencephalopathy (PML), caused by an 
infection with the John Cunningham Virus (JCV), is a rare disease 
that in the past was mainly related to human immunodeficiency virus 
(HIV) infections and blood cancers like leukemia or lymphoma [1]. 
However, PML also occurs as an adverse event during natalizumab 
(NTZ) therapy [2], an α4-integrin inhibitor, for relapsing–remitting 
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Background and purpose: Progressive multifocal leukoencephalopathy (PML), an oppor-
tunistic infection of the central nervous system from the John Cunningham virus (JCV), 
is a side effect of natalizumab (NTZ) treatment for relapsing–remitting multiple sclero-
sis (RRMS), potentially leading to a substantial increase of physical and mental disabil-
ity. Nevertheless, data of neuropsychological impairment during the NTZ-PML disease 
course are missing. Our objective was to evaluate the neuropsychological disease course 
of NTZ-PML patients and to compare neuropsychological deficits of NTZ-PML patients 
with two different non-PML multiple sclerosis (MS) cohorts.
Methods: Neuropsychological examinations of 28 NTZ-PML patients performed during 
different phases of the disease ([i] at PML diagnosis, [ii] during immune reconstitution 
inflammatory syndrome [IRIS], and [iii] post-IRIS/PML) were retrospectively analyzed and 
compared to those of NTZ-treated RRMS or secondary progressive MS patients with and 
without immunotherapy.
Results: Compared to controls, NTZ-PML patients performed worse in neuropsychologi-
cal examinations during all stages of disease, mainly affecting visuospatial ability and 
working memory. Furthermore, failure to eliminate the JCV from the central nervous sys-
tem was associated with a progredient decline of cognition, especially working memory.
Conclusions: Working memory and visuospatial abilities are the core neuropsychological 
deficits of NTZ-PML patients in long-term follow-up. Our findings should be implemented 
in neurorehabilitation strategies.
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multiple sclerosis (RRMS) [3]. By 5 September 2018, 795 NTZ-treated 
RRMS patients developed NTZ-PML, resulting in an incidence of 
4.17 per 1000 NTZ-treated patients, of whom 24% died [4]. No an-
tiviral therapy exists, and early diagnosis to enable early discontin-
uation of NTZ therapy was found to positively influence NTZ-PML 
survival [5]. We have previously demonstrated that neuropsycholog-
ical impairment, especially a deterioration of visuospatial ability and 
working memory, are often present at the beginning of NTZ-PML 
and might therefore support NTZ-PML diagnosis [6]. Interestingly, 
these deficits of NTZ-PML patients were also observed in an inde-
pendent cohort of HIV-infected individuals with PML [7], pointing to 
a probable PML type pattern of neuropsychological deterioration.
To more precisely describe neuropsychological deterioration 
during the course of NTZ-PML, in this article we aimed to investi-
gate the course of neuropsychological impairment during the NTZ-
PML disease course and compare neuropsychological findings of 
NTZ-PML patients with two multiple sclerosis (MS) control groups: 
NTZ-treated RRMS and secondary progressive MS (SPMS) patients.
METHODS
The ethics committee of Ruhr University Bochum approved this ret-
rospective observational study (no. 4566-13). All patients (22 RRMS, 
74 SPMS, 28 NTZ-PML (some patients previously published in Kinner 
et al. [8] (neuropsychological impairment in the SPMS control group), 
Hoepner et al. [9] (neuropsychological impairments at PML diagno-
sis), and Hoepner et al. [6] (longitudinal clinical outcome of PML pa-
tients) (Table S1))) were identified by retrospective analysis of medical 
records. RRMS and NTZ-PML groups were matched in terms of age 
at MS diagnosis, age, and Expanded Disability Status Scale (EDSS) 
at first neuropsychological examination (NPE), immunosuppression 
before NTZ start, and sex. Only duration of NTZ treatment differed 
significantly, with a longer duration in patients who developed NTZ-
PML. Longitudinal NPEs were performed in a standardized manner 
as used in our clinical practice and described in Kinner et al. [8]. The 
battery is composed of the Multiple Choice Vocabulary Intelligence 
Test as a test for crystallized intelligence and linguistic skills, d2 test 
as a test for attention and information processing speed, German 
Performance Testing System subtests 3 (deductive thinking) and 7 
(visuospatial abilities), Regensburg Word Fluency Test subtest lexical 
word fluency (linguistic skills and crystallized intelligence) and lexical 
category change (cognitive flexibility as a domain of executive func-
tion and linguistic skills), Verbal Learning and Memory Test A (short-
term memory and linguistic skills), Wechsler Memory Scale Subtests 
Visual Reproduction I (visuospatial abilities and working memory), 
Digit Span Forward and Backward (working memory), and Shulman 
Clock Drawing Test (visuospatial abilities and crystal intelligence).
Relapsing–remitting multiple sclerosis patients diagnosed with 
NTZ-PML underwent an NPE at three time points during their dis-
ease course: (i) at diagnosis (n = 21; 9.0 ± 17 days after diagnosis), (ii) 
at immune reconstitution inflammatory syndrome (IRIS; defined as 
gadolinium enhancing PML-lesions in magnetic resonance imaging 
[MRI]; n = 10; 10.0 ± 47.3 days after first gadolinium enhancement 
in MRI), and (iii) post-IRIS/PML (n = 16; 19.0 ± 32.5 months after 
first gadolinium-negative MRI in patients with positive JCV poly-
merase chain reaction [PCR] at last follow-up or after proof of JCV 
PCR negativity in cerebrospinal fluid [CSF]); all PCR-analyses were 
performed at the Department of Virology, University of Düsseldorf). 
Four patients of this post-IRIS-cohort were JCV noneliminators, as 
they were JCV positive in CSF testing at the time of their last NPE 
(24 ± 31 months after NTZ-PML diagnosis and 4.5 ± 34.5 months 
after first gadolinium-negative MRI).
Compared to NTZ-PML patients, where an NPE was performed 
during ongoing active encephalitis (at early PML and PML-IRIS, as 
well as for JCV noneliminators also at post-IRIS), in all MS controls 
(NTZ-RRMS and SPMS), NPEs were performed during a phase of MS 
disease without any acute MS exacerbation. Treatment of SPMS pa-
tients was intravenous (IV) mitoxantrone (42/74; cumulative dose: 
49.0 ± 29.5 mg/m2 body surface) or intrathecal triamcinolone ace-
tate (32/74; 40–160 mg every 3–4 months).
All values are presented as median ± interquartile range. To de-
tect differences in neuropsychological tests between PML patients 
and each control, Mann-Whitney U tests were performed using 
SPSS (IBM, Armonk, NY, USA).
RESULTS
Characteristics of study populations
Natalizumab-PML patients and control groups did not differ in age 
at MS diagnosis and sex. Whereas, age at NPE and disability as 
measured by the EDSS differed between groups, with SPMS con-
trols being significantly older (SPMS: 47.5 ± 14.0, RRMS: 37.5 ± 16.8, 
and NTZ-PML: 39.5 ± 11.8 years, both p < 0.05; Table 1) and more 
disabled than the NTZ-PML patients and the RRMS controls (SPMS: 
6.0 ± 1.5, RRMS: 3.0 ± 2.5, NTZ-PML: 4.0 ± 2.8, each p < 0.05; 
Table 1). Furthermore, NTZ-PML patients had a significantly longer 
duration of NTZ therapy than the NTZ-treated control group (NTZ-
PML: 48.0 ± 36.0, NTZ: 25.0 ± 26.2 months, p < 0.05; Table 1).
Neuropsychological profile of NTZ-PML patients 
compared to MS controls
Using the Beck Depression Inventory-II, no differences in depressive 
symptoms were found between NTZ-PML patients and both inde-
pendent MS control groups (NTZ: 12.0 ± 14.5; SPMS: 10.0 ± 10.0; 
early PML: 10.0 ± 9.5; PML-IRIS: 8.0 ± 8.0; post-IRIS/PML: 8.0 ± 8.0; 
all p > 0.05; Table 2).
Natalizumab-PML patients performed significantly worse in 
Shulman Clock Drawing Test (SCD) at all time points than NTZ-
treated RRMS patients (NTZ: 1 ± 0; early PML: 3 ± 2 [vs. NTZ 
p < 0.001]; PML-IRIS: 3 ± 1 [vs. NTZ p < 0.001]; post-IRIS/PML: 1 ± 2 
[vs. NTZ p < 0.01]). Compared to SPMS patients (SCD [SPMS]: 1 ± 1), 
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differences were only detected shortly postdiagnosis prior to IRIS 
(p < 0.05) and during the IRIS phase (p < 0.01) of NTZ-PML (Table 2, 
Figure 1).
In addition to visuospatial ability, working memory, tested by 
the Digit Span Backward test (WMS-R_DSB), was affected in NTZ-
PML patients with pronounced deficits during all phases of disease 
compared to NTZ-treated RRMS and SPMS controls (NTZ: 7.0 ± 3.0; 
SPMS: 6.0 ± 2.0; early PML: 4.0 ± 3.0 (vs. NTZ: p < 0.001; vs. SPMS: 
p < 0.001); PML-IRIS: 3.5 ± 4.0 (vs. NTZ: p < 0.001; vs. SPMS: 
p < 0.05); post-IRIS/PML: 5.0 ± 2.0 (vs. NTZ: p < 0.001; vs. SPMS: 
p < 0.05); Table 2, Figure 2).
Neuropsychological profile of NTZ-PML patients 
with and without elimination of JCV from the central 
nervous system
Natalizumab-PML patients with and without JCV elimination from 
the CSF did not differ in steroid administration during IRIS or NTZ-
PML treatment protocol (data not shown). Comparing NTZ-PML 
patients who successfully eliminated the JCV from the CSF with 
those who remained JCV positive during follow-up unmasked a 
predominant decline in cognitive function in the patient population 
who did not eliminate the JCV in a wide range of NPEs: (i) SCD (JCV 
negative: 1 ± 1, JCV positive: 5 ± 1; p < 0.01; Figure 1), (ii) Multiple 
Choice Vocabulary Test (JCV-negative: 30 ± 5, JCV positive: 15.5 ± 7; 
p < 0.001; Figure 3), (iii) Verbal Learn and Memory Test (VLMT; fifth 
repetition: JCV negative: 14 ± 1.5, JCV positive: 11 ± 6; p < 0.05; sev-
enth repetition: JCV negative: 12 ± 3, JCV positive: 3 ± 9; p < 0.05). 
Analyzing an association between the amount of JCV copy numbers 
in the CSF and post-IRIS/PML cognitive performance of all NTZ-PML 
patients demonstrated a worse cognitive outcome in those with 
higher JCV copy numbers in the CSF in the Digit Span Backward 
test, Digit Span Forward test, VLMT (first and seventh repetition, as 
well as interference round), and German Performance Test subtest 3 
(each p < 0.05; Pearson correlation; Table 2).
DISCUSSION
This is the first study to describe neuropsychological dysfunction 
during different phases of the NTZ-PML disease course using a 
standardized test battery in the largest NTZ-PML cohort treated in 
a single center. As previously demonstrated in a smaller cohort of 
TA B L E  1  Basic characteristics of NTZ-PML patients, RRMS, and SPMS controls
PML NTZ SPMS
n 28 22 74
Sex, m/f 10/18 7/15 25/49
Age at first NPE, years, median [IQR] 39.5 [34.0–45.8]* 37.5 [27.5–44.3]* 47.5 [41.0–55.0]
Age at MS diagnosis, years, median [IQR] 28 [21–34]* 28 [23–35] 34.0 [27–43]
EDSS at first assessment, median [IQR] 4.0 [3.1–5.9]* 3.0 [1.5–4.0]* 6.0 [5.0–6.5]
Immunosuppression, before NTZ start, yes/no/no data 5/21/2 3/18/1 42/32/0
NTZ-duration, months, median [IQR] 48.0 [30.3–66.3]** 25.0 [13.8–40]
PML diagnosis until first NPE, days, median [IQR] 9.0 [4.0–21.0] n = 21
IRIS (first Gd + MRI) until second NPE, days, median [IQR] 10.0 [1.5–48.8] n = 10
JCV-negative or Gd-negative until third NPE, months, median [IQR] 19.0 [0.3–32.8] n = 16
Gd-negative until third NPE if JCV-positive at third NPE, months, 
median [IQR]
4.5 [0.0–34.5] n = 4
JCV-negative until third NPE, months, median [IQR] 21.5 [4.0–32.8] n = 12
PLEX before IRIS, yes/no 20/7
IA before IRIS, yes/no 17/10




Steroids in IRIS, yes/no/no data 24/3/1 (3/1 of continuously 
JCV-positive)
Note: Mann-Whitney U test for continuous and Fisher exact test for dichotomous variables.
Abbreviations: EDSS, Expanded Disability Status Scale; Gd, gadolinium; IA, immunoadsorption; IQR, interquartile range; IRIS, immune reconstitution 
inflammatory syndrome; JCV, John Cunningham virus; MRI, magnetic resonance imaging; MS, multiple sclerosis; NPE, neuropsychological 
examination; NTZ, natalizumab; PLEX, plasmapheresis; PML, progressive multifocal leukoencephalopathy; SPMS, secondary progressive MS.
*Significant differences versus SPMS; each p < 0.05. 
**Significant differences versus NTZ. 
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eight NTZ-PML patients [6] and again validated by our study, all NTZ-
PML patients had neuropsychological abnormalities in formal test-
ing, highlighting the relevance of this symptom in NTZ-PML patients.
First, our NTZ-PML cohort demonstrated a deterioration in all 
tests during the IRIS phase, with a trend to recovery at the last 
time point (Table 2) if JCV was eliminated from the CSF. In con-
trast, in NTZ-PML patients who were not able to eliminate the 
virus from the central nervous system, a pronounced deterioration 
of neuropsychological function was seen, which also matches the 
clinical course of these patients (clinical course excluding neuro-
psychological findings of all patients as reported in Hoepner et al. 
[9]) without clear difference during PML but a worse recovery 
of disabilities caused by PML. Also, the previously shown core 
neuropsychological deficits of NTZ-PML patients (working mem-
ory and visuospatial abilities) [6] were markedly affected in con-
tinuously JCV-positive NTZ-PML patients. In addition, we could 
demonstrate a negative correlation between the highest JCV copy 
number in the CSF and working memory performance at last neu-
ropsychological assessment post-PML in all NTZ-PML patients. In 
our view, this provides additional proof that JCV infection is asso-
ciated with progressing cognitive decline, especially in the previ-
ously mentioned core domains [6].
As our study included an RRMS as well as a SPMS cohort, our 
finding of a PML-related core neuropsychological deficit could be 
distinguished from MS-related cognitive decline. A decline in pro-
cessing speed in RRMS patients and a decline in frontal executive 
functions in SPMS patients have been previously demonstrated as 
core neuropsychological deficits [10,11]. In SPMS, as a model for the 
neurodegenerative and chronic progressive phase of MS, affected 
cognitive fields also differed from NTZ-PML, which pronounces the 
distinction of NTZ-PML core cognitive deficits.
The main limitation of our retrospective study is the miss-
ing data at several time points of NTZ-PML. These missing val-
ues were caused by the retrospective nature of our study, which 
prohibits a direct intraindividual comparison of NPEs at different 
phases of NTZ-PML. The neuropsychological test battery used 
is adjusted to scan for neuropsychological deficits in our clinical 
routine. Therefore, some cognitive domains (especially executive 
functions) might be underrepresented. Overall, the NTZ-PML and 
RRMS groups are well matched. However, it should be noted that 
the NTZ-PML group has a longer NTZ therapy duration than the 
RRMS group. Matching based on MRI was not possible due to miss-
ing MRI data in the RRMS group. As EDSS at the first NPE does not 
differ, we do not think that this is due to a higher disease activity 
before starting NTZ. In contrast, NTZ therapy is associated with 
cognitive stability or even improvement in some studies [12], so 
that a more severe cognitive effect of NTZ-PML patients by MS 
disease seems unlikely.
F I G U R E  1  Shulman Clock Drawing Test compared to study group and phase of NTZ-PML. Mann-Whitney U test. #NTZ-PML versus 
SPMS, p < 0.05; ##p < 0.01; **NTZ-PML versus ;NTZp < 0.01; ***p < 0.001; ++NTZ-PML JCV-negative versus NTZ-PML JCV-positive; 
p < 0.01. IRIS, immune reconstitution inflammatory syndrome; JCV, John Cunningham virus; neg., negative; NTZ, natalizumab; PML, 
progressive multifocal leukoencephalopathy; pos., positive; SPMS, secondary progressive multiple sclerosis
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F I G U R E  2  Wechsler Memory Scale–Digit Span Backward Test compared to the study group and phase of NTZ-PML. Mann-Whitney 
U test. #NTZ-PML versus SPMS, p < 0.05; ###p < 0.001; ***NTZ-PML versus NTZ; p < 0.001. IRIS, immune reconstitution inflammatory 
syndrome; JCV, John Cunningham virus; neg., negative; NTZ, natalizumab; PML, progressive multifocal leukoencephalopathy; pos., positive; 
SPMS, secondary progressive multiple sclerosis
F I G U R E  3  Multiple Choice Vocabulary Test compared to the study group and phase of NTZ-PML. Mann-Whitney U test. +++NTZ-PML 
JCV-negative versus NTZ-PML JCV-positive; p < 0.001. IRIS, immune reconstitution inflammatory syndrome; JCV, John Cunningham virus; 
NTZ, natalizumab; PML, progressive multifocal leukoencephalopathy; SPMS, secondary progressive multiple sclerosis
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In addition to the limitations of the retrospective design, the 
NTZ-PML treatment, which can also affect cognition, must be 
highlighted. Our NTZ-PML patients were treated in a standardized 
fashion (Wenning et al.) [13], which included plasma exchange and 
immunoadsorption, mefloquine [14], mirtazapine [15], and prophy-
lactic antiepileptic medication with levetiracetam [16]. In addition, 
during the IRIS phase, high-dose corticosteroids were used to pre-
vent overshooting immunological damage. However, as the same 
qualitative profile of neurocognitive findings was also demonstrated 
after elimination of JCV, when medications for NTZ-PML treatment 
had already been withdrawn, a confounding effect of this treatment 
regime appears to be minor.
In conclusion, our data demonstrate working memory and vi-
suospatial abilities as core neuropsychological deficits of NTZ-PML 
patients even in long-term follow-up. Fast JCV elimination from the 
CSF seems to protect against ongoing neuropsychological deterio-
ration caused by NTZ-PML. Thus, our findings argue for a prompt 
and consequent treatment of NTZ-PML. As neuropsychological ab-
normalities were already present during early disease stages, NPE 
should be integrated in the diagnostic workup of suspected NTZ-
PML. Finally, the description of the residual post-PML neuropsycho-
logical deficit should stimulate the development of rehabilitation 
programs tailored to the needs of NTZ-PML patients to support so-
cial reintegration.
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